Skip to content
10-Q

Quarterly Report

TransMedics Group, Inc. TMDX

0001193125-26-206453

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 34.56M sh
Shares Diluted Q1 2026 · Mar 31, 2026 36.19M sh
Shares Diluted Q1 2026 · Mar 31, 2025 39.91M sh
Capex Q1 2026 · Mar 31, 2026 $36.66M
Capex Q1 2026 · Mar 31, 2025 $27.04M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $24.53M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.86M
Short Term Debt Q1 2026 · Mar 31, 2026 $15M
Short Term Debt Q1 2026 · Dec 31, 2025 $10M
Stockholders Equity Q1 2026 · Mar 31, 2026 $494.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $473.1M
Stockholders Equity Q1 2026 · Mar 31, 2025 $266.31M
Stockholders Equity Q1 2026 · Dec 31, 2024 $228.6M
Current Liabilities Q1 2026 · Mar 31, 2026 $91.92M
Current Liabilities Q1 2026 · Dec 31, 2025 $89.31M
Total Liabilities Q1 2026 · Mar 31, 2026 $940.81M
Total Liabilities Q1 2026 · Dec 31, 2025 $595.27M
Current Assets Q1 2026 · Mar 31, 2026 $619.28M
Current Assets Q1 2026 · Dec 31, 2025 $637.78M
Total Assets Q1 2026 · Mar 31, 2026 $1.43B
Total Assets Q1 2026 · Dec 31, 2025 $1.07B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.20
Eps Diluted Q1 2026 · Mar 31, 2025 $0.70
Eps Basic Q1 2026 · Mar 31, 2026 $0.21
Eps Basic Q1 2026 · Mar 31, 2025 $0.76
Sga Expense Q1 2026 · Mar 31, 2026 $62.99M
Sga Expense Q1 2026 · Mar 31, 2025 $43.63M
Rd Expense Q1 2026 · Mar 31, 2026 $24.88M
Rd Expense Q1 2026 · Mar 31, 2025 $17.16M
Net Income Q1 2026 · Mar 31, 2026 $7.32M
Net Income Q1 2026 · Mar 31, 2025 $25.68M
Operating Income Q1 2026 · Mar 31, 2026 $13.3M
Operating Income Q1 2026 · Mar 31, 2025 $27.44M
Gross Profit Q1 2026 · Mar 31, 2026 $101.16M
Gross Profit Q1 2026 · Mar 31, 2025 $88.23M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $72.77M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $55.31M